{"product_id":"oncology-gene-therapy-markets","title":"Oncology Gene Therapy Markets","description":"\u003cp\u003e\u003cstrong\u003eOncology Gene Therapy: Market Forecast, Competitive Landscape and Strategic Opportunities, 2027–2031\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlobal forecasts by approach, vector, indication, product and route of administration, with country and regional breakouts and 15 company profiles.\u003c\/p\u003e\n\u003cdiv style=\"margin:24px 0;padding:20px 24px;border:2px solid #1f3a5f;border-radius:8px;text-align:center;\"\u003e\n\u003cp style=\"margin:0 0 6px;font-size:1.15em;\"\u003e\u003cstrong\u003eSee inside before you buy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin:0 0 16px;\"\u003eGet a free sample: the full table of contents plus real pages of analysis, company profiles, tables and charts.\u003c\/p\u003e\n\u003cp style=\"margin:0;\"\u003e\u003ca href=\"\/pages\/request-a-sample?report=ONCGENE\" style=\"display:inline-block;padding:12px 28px;background:#1f3a5f;color:#ffffff;text-decoration:none;border-radius:6px;font-weight:bold;\"\u003eRequest a free sample\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eOur Take\u003c\/h3\u003e\n\u003cp\u003eOncology gene therapy is a CAR-T market, and it is becoming a myeloma market. We forecast the market to nearly double, from $7.1 billion in 2026 to $13.6 billion in 2031, with Carvykti alone reaching $5.1 billion. The first CAR-T products are fading, bladder cancer is the one real growth story outside CAR-T, and in vivo CAR-T, despite billions spent on acquisitions, is a story for after 2031 rather than a driver of this forecast.\u003c\/p\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/ONCGENE_Key_Graphic.png?v=1792523701\" alt=\"The CAR-T changing of the guard: oncology gene therapy product sales, 2026 to 2031\" style=\"width:100%;height:auto;\"\u003e\u003c\/p\u003e\n\u003ch3\u003eSituation Analysis: what is really happening\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMyeloma overtakes lymphoma. \u003c\/strong\u003eBCMA CAR-T therapies lift myeloma revenue from $2.8 billion to $5.4 billion, making it the largest indication by 2031, and Carvykti grows to 37% of the market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe first generation fades. \u003c\/strong\u003eKymriah, Abecma and Tecartus decline by about 14% a year as Breyanzi, Carvykti and bispecific antibodies take their patients.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBladder cancer is the breakout outside CAR-T. \u003c\/strong\u003eAdstiladrin grows six-fold to $450 million, and cretostimogene and the non-viral detalimogene are approaching regulatory filings.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBig pharma paid early for the next generation. \u003c\/strong\u003eGilead's $7.8 billion Arcellx deal and about $5 billion of in vivo CAR-T acquisitions buy future options, but we expect little in vivo revenue before 2031.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompany Analysis: who is positioned, who is exposed\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eJohnson \u0026amp; Johnson \/ Legend Biotech: \u003c\/strong\u003eCarvykti is the market leader and its main growth engine, reaching $5.1 billion by 2031. Legend depends almost entirely on it.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBristol Myers Squibb: \u003c\/strong\u003eBreyanzi is the fastest-growing CD19 CAR-T, while Abecma loses share in myeloma. The Orbital acquisition adds an in vivo platform.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGilead (Kite): \u003c\/strong\u003eYescarta and Tecartus are declining, so its outlook depends on anito-cel, with an FDA decision due in December 2026.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFerring: \u003c\/strong\u003eAdstiladrin leads bladder cancer gene therapy, but competition arrives from 2027.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCG Oncology: \u003c\/strong\u003eCretostimogene's 75.5% complete response rate makes it the leading bladder challenger, with its filing due to complete in the fourth quarter of 2026.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReplimune: \u003c\/strong\u003eRP1's accelerated approval after two rejections is the test of whether oncolytic viruses can succeed commercially.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePlus 9 more company profiles covering big pharma buyers, in vivo CAR-T developers and emerging cell therapy companies.\u003c\/p\u003e\n\u003ch3\u003eQuestions this report answers\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eHow fast will oncology gene therapy grow, and which products drive it?\u003c\/li\u003e\n\u003cli\u003eWhen does multiple myeloma overtake lymphoma as the largest CAR-T market?\u003c\/li\u003e\n\u003cli\u003eHow quickly will the first CAR-T products lose share to Breyanzi, Carvykti and bispecific antibodies?\u003c\/li\u003e\n\u003cli\u003eHow big can bladder cancer gene therapy become, and who will lead it?\u003c\/li\u003e\n\u003cli\u003eWhen will in vivo and allogeneic CAR-T generate real revenue?\u003c\/li\u003e\n\u003cli\u003eHow do cost and manufacturing capacity limit CAR-T uptake?\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eWhat’s inside\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e171 pages, 23 chapters\u003c\/li\u003e\n\u003cli\u003e15 company profiles with technology, pipeline, strategy and risks\u003c\/li\u003e\n\u003cli\u003eForecasts 2027–2031 from a 2026 base (actual) year, by approach, vector, indication, product and route of administration, for 14 countries and regions\u003c\/li\u003e\n\u003cli\u003eApproved product registry and 2025 sales benchmarks\u003c\/li\u003e\n\u003cli\u003eClinical pipeline, manufacturing and supply chain, regulation and reimbursement, and a China ecosystem chapter\u003c\/li\u003e\n\u003cli\u003eDelivered as 3 files: full report PDF, Situation Analysis PDF, and Excel workbook of all charts and tables\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/ONCGENE_1026_Table_of_Contents.pdf\" target=\"_blank\" rel=\"noopener\"\u003eDownload the Table of Contents (PDF)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv style=\"margin:24px 0;padding:20px 24px;border:2px solid #1f3a5f;border-radius:8px;text-align:center;\"\u003e\n\u003cp style=\"margin:0 0 6px;font-size:1.15em;\"\u003e\u003cstrong\u003eSee inside before you buy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin:0 0 16px;\"\u003eGet a free sample: the full table of contents plus real pages of analysis, company profiles, tables and charts.\u003c\/p\u003e\n\u003cp style=\"margin:0;\"\u003e\u003ca href=\"\/pages\/request-a-sample?report=ONCGENE\" style=\"display:inline-block;padding:12px 28px;background:#1f3a5f;color:#ffffff;text-decoration:none;border-radius:6px;font-weight:bold;\"\u003eRequest a free sample\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eWho buys this report\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBusiness development and licensing teams: \u003c\/strong\u003efind acquisition and in-licensing candidates and track next-generation platforms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestors and equity analysts: \u003c\/strong\u003emodel CAR-T share shifts and the timing of next-generation approaches.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCell and gene therapy developers: \u003c\/strong\u003echoose the indications, targets and delivery approaches with the most room to grow.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eManufacturers and suppliers: \u003c\/strong\u003esize vector and manufacturing demand by approach and vector.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eLicences and support\u003c\/h3\u003e\n\u003cp\u003eYour order is delivered to your inbox immediately. Every licence includes unlimited questions to the analyst and custom data breakouts, including any country not shown. Single User, Five User and Enterprise licences contain the same report; they differ only in how many people may use it.\u003c\/p\u003e\n\u003ch3\u003eAbout the author\u003c\/h3\u003e\n\u003cp\u003eGreg Powell, B.Sc., M.B.A., has worked in laboratory testing and management for more than 20 years, with executive training at Harvard Business School and the Burke Institute.\u003c\/p\u003e","brand":"OncoPharma Insights","offers":[{"title":"Single User","offer_id":67817564110927,"sku":null,"price":6995.0,"currency_code":"USD","in_stock":true},{"title":"Five User","offer_id":67817564143695,"sku":null,"price":9995.0,"currency_code":"USD","in_stock":true},{"title":"Enterprise License","offer_id":67817564176463,"sku":null,"price":13995.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/ONCGENE_1026_Cover.png?v=1792523985","url":"https:\/\/oncopharmainsights.com\/products\/oncology-gene-therapy-markets","provider":"OncoPharma Insights","version":"1.0","type":"link"}